Do Amyloid β-associated factors co-deposit with Aβ in mouse models for Alzheimer's disease?

Journal of Alzheimer's Disease

Volumn 22, Issue 2, 2010, Pages 345-355

  Timmer, Nienke M ^a   Kuiperij, H Bea ^a   De Waal, Robert M W ^b   Verbeek, Marcel M ^a  

^a RADBOUD UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute phase proteins; Alzheimer's disease; amyloid ; apolipoprotein E; complement; heparan sulfate proteoglycans; transgenic mice

Indexed keywords

AGRIN; ALPHA 2 MACROGLOBULIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; CLUSTERIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C7; COMPLEMENT COMPONENT C9; CYSTATIN C; GLYPICAN 1; HEPARAN SULFATE; INTERCELLULAR ADHESION MOLECULE 1; PERLECAN; SERUM AMYLOID P; SYNDECAN 3;

ALZHEIMER DISEASE; COMPLEMENT FACTOR; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TRANSGENE;

EID: 78650833299     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100711     Document Type: Review

References (118)

1. Glenner GG, Wong CW (1984) Alzheimer's disease: initial report ofthe purification and characterization ofa novel cere-brovascular amyloid protein. Biochem Biophys Res Commun 120, 885-890.
2. Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Harigaya Y (1988) Diffuse type of senile plaques in the brains of Alzheimer-type dementia. Acta Neuropathol 77, 113-119.
3. Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8, 663-672.
4. Sperling RA, Dickerson BC, Pihlajamaki M, Vannini P, LaVi-olette PS, Vitolo OV, Hedden T, Becker JA, Rentz DM, Selkoe DJ, Johnson KA (2010) Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med 12, 27-43.
5. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
6. Tandon A, Rogaeva E, Mullan M, St George-Hyslop PH (2000) Molecular genetics of Alzheimer's disease: the role of beta-amyloid and the presenilins. Curr Opin Neurol 13, 377-384.
7. Citron M (2000) Identifying proteases that cleave A(PP). Ann NY Acad Sci 920, 192-196.
8. Wolfe MS (2001) Secretase targets for Alzheimer's disease: identification and therapeutic potential. J Med Chem 44, 2039-2060.
9. De Strooper B., Vassar R, Golde T (2010) The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 6, 99-107.
10. Brunkan AL, Goate AM (2005) Presenilin function and gamma-secretase activity. J Neurochem 93, 769-792.
11. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomensaari SM, Wang S, Walker D, Zhao J, McConlogue L, John V (1999) Purification and cloning ofamyloid precursor protein beta-secretase from human brain. Nature 402, 537-540.
12. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Tre-anor J, Rogers G, Citron M (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmem-brane aspartic protease BACE. Science 286, 735-741.
13. Brouwers N, Sleegers K, Van Broeckhoven C (2008) Molecular genetics of Alzheimer's disease: an update. Ann Med 40, 562-583.
14. Wolfe MS, Haass C (2001) The Role of presenilins in gamma-secretase activity. J Biol Chem 276, 5413-5416.
15. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS (1996) Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17, 1005-1013.
16. Sarasa M, Pesini P (2009) Natural non-trasgenic animal models for research in Alzheimer's disease. Curr Alzheimer Res 6, 171-178.
17. Games D, Buttini M, Kobayashi D, Schenk D, Seubert P (2006) Mice as models: transgenic approaches and Alzheimer's disease. J Alzheimers Dis 9, 133-149.
18. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Lei-bowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373, 523-527.
19. Dodart JC, Meziane H, Mathis C, Bales KR, Paul SM, Ungerer A (1999) Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Behav Neurosci 113, 982-990.
20. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, Turner S, Lozza G, Grilli M, Kunicki S, Morissette C, Paquette J, Gervais F, Bergeron C, Fraser PE, Carlson GA, George-Hyslop PS, Westaway D (2001) Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein JBiol Chem 276, 21562-21570.
21. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102.
22. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13, 159-170.
23. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4, 97-100.
24. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer diseaselike pathology. Proc Natl Acad Sci USA 94, 13287-13292.
25. Davis J, Xu F, Deane R, Romanov G, Previti ML, Zeigler K, Zlokovic BV, Van Nostrand WE (2004) Early-onset and robust cerebral microvascular accumulation ofamyloid beta-protein in transgenic mice expressing low levels of a vas-culotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem 279, 20296-20306.
26. Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tol-nay M, Wiederhold KH, Abramowski D, Sturchler-Pierrat C, Sommer B, Staufenbiel M, Jucker M (1999) Neuronal over-expression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci USA 96, 14088-14093.
27. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, Danner S, Abramowski D, Sturchler-Pierrat C, Burki K, van Duinen SG, Maat-Schieman ML, Staufen-biel M, Mathews PM, Jucker M (2004) Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 7, 954-960.
28. Gotz J, Chen F, Barmettler R, Nitsch RM (2001) Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 276, 529-534.
29. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van SM, Gwinn-Hardy K, Paul MM, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25, 402-405.
30. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421.
31. Kalback W, Watson MD, Kokjohn TA, Kuo YM, Weiss N, Luehrs DC, Lopez J, Brune D, Sisodia SS, Staufenbiel M, Emmerling M, Roher AE (2002) AftPP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry 41, 922928.
32. Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, Kalback WM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Roher AE (2001) Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology oftransgenic mouse and Alzheimer's disease brains. JBiol Chem 276, 12991-12998.
33. Van Vickle GD, Esh CL, Daugs ID, Kokjohn TA, Kalback WM, Patton RL, Luehrs DC, Walker DG, Lue LF, Beach TG, Davis J, Van Nostrand WE, Castano EM, Roher AE (2008) Tg-SwDI transgenic mice exhibit novel alterations in AbetaPP processing, Abeta degradation, and resilient amyloid angiopathy. Am J Pathol 173, 483-493.
34. Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, Staufenbiel M, Sommer B, Jucker M (1998) Neuron loss in AftPP transgenic mice. Nature 395, 755-756.
35. Verbeek MM, Otte-Holler I, Veerhuis R, Ruiter DJ, de Waal RM (1998) Distribution of A beta-associated proteins in cerebrovascular amyloid of Alzheimer's disease. Acta Neu-ropathol (Berl) 96, 628-636.
36. Wilhelmus MM, de Waal RM, Verbeek MM (2007) Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer's disease. Mol Neu-robiol 35, 203-216.
37. Abraham CR, Potter H (1989) The protease inhibitor, alpha 1-antichymotrypsin, is a component of the brain amyloid deposits in normal aging and Alzheimer's disease. Ann Med 21,77-81.
38. Ma J, Yee A, Brewer HB, Jr., Das S, Potter H (1994) Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372, 92-94.
39. van Horssen J, Wesseling P, van den Heuvel LP, de Waal RM, Verbeek MM (2003) Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol 2, 482-492.
40. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B (1994) Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 145, 1030-1035.
41. Snow AD, Mar H, Nochlin D, Kimata K, Kato M, Suzuki S, Hassell J, Wight TN (1988) The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. Am J Pathol 133, 456-463.
42. van Horssen J, Otte-Holler I, David G, Maat-Schieman ML, van den Heuvel LP, Wesseling P, de Waal RM, Verbeek MM (2001) Heparan sulfate proteoglycan expression in cere-brovascular amyloid beta deposits in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains. Acta Neuropathol (Berl) 102, 604-614.
43. Cotman SL, Halfter W, Cole GJ (2000) Agrin binds to beta-amyloid (Abeta), accelerates abeta fibril formation, and is localized to Abeta deposits in Alzheimer's disease brain. Mol CellNeurosci 15, 183-198.
44. van Horssen J, Kleinnijenhuis J, Maass CN, Rensink AA, Otte-Holler I, David G, van den Heuvel LP, Wesseling P, de Waal RM, Verbeek MM (2002) Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques. Neurobiol Aging 23, 537-545.
45. Snow AD, Kinsella MG, Parks E, Sekiguchi RT, Miller JD, Kimata K, Wight TN (1995) Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease. Arch Biochem Biophys 320, 84-95.
46. Castillo GM, Ngo C, Cummings J, Wight TN, Snow AD (1997) Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. J Neurochem 69, 24522465.
47. Castillo GM, Lukito W, Wight TN, Snow AD (1999) The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. J Neurochem 72, 1681-1687.
48. Bornemann KD, Staufenbiel M (2000) Transgenic mouse models of Alzheimer's disease. Ann N Y Acad Sci 908, 260266.
49. O'Callaghan P, Sandwall E, Li JP, Yu H, Ravid R, Guan ZZ, van Kuppevelt TH, Nilsson LN, Ingelsson M, Hyman BT, Kalimo H, Lindahl U, Lannfelt L, Zhang X (2008) Heparan sulfate accumulation with Abeta deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells. Brain Pathol 18, 548-561.
50. Timmer NM, Herbert MK, Kleinovink JW, Kiliaan AJ, de Waal RM, Verbeek MM (2010) Limited expression of hep-aran sulfate proteoglycans associated with Abeta deposits in the AftPPswe/PS 1dE9 mouse model for Alzheimer's disease. Neuropathol Appl Neurobiol 36, 478-486.
51. Kokjohn TA, Roher AE (2009) Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement 5, 340-347.
52. Snow AD, Wight TN (1989) Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiol Aging 10, 481-497.
53. Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM (1985) Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest 76, 1501-1513.
54. Bruinsma IB, Wilhelmus MM, Kox M, Veerhuis R, de Waal RM, Verbeek MM (2010) Apolipoprotein E protects cultured pericytes and astrocytes from D-Abeta(1-40)-mediated cell death. Brain Res 1315, 169-180.
55. Wilhelmus MM, Otte-Holler I, Davis J, Van Nostrand WE, de Waal RM, Verbeek MM (2005) Apolipoprotein E genotype regulates amyloid-beta cytotoxicity. J Neurosci 25, 36213627.
56. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH (1987) Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. JBiol Chem 262, 14352-14360.
57. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipopro-tein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90, 1977-1981.
58. Kim J, Basak JM, Holtzman DM (2009) The role of apolipoprotein E in Alzheimer's disease. Neuron 63, 287-303.
59. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K (1991) Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 541, 163-166.
60. Navarro A, Del VE, Astudillo A, Gonzalez del RC, Tolivia J (2003) Immunohistochemical study of distribution of apolipoproteins E and D in human cerebral beta amyloid deposits. Exp Neurol 184, 697-704.
61. Wisniewski T, Frangione B (1992) Apolipoprotein E: apatho-logical chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 135, 235-238.
62. Sheng JG, Mrak RE, Griffin WS (1996) Apolipoprotein E distribution among different plaque types in Alzheimer's disease: implications for its role in plaque progression. Neu-ropathol Appl Neurobiol 22, 334-341.
63. Kuo YM, Crawford F, Mullan M, Kokjohn TA, Emmer-ling MR, Weller RO, Roher AE (2000) Elevated A beta and apolipoprotein E in A betaPP transgenic mice and its relationship to amyloid accumulation in Alzheimer's disease. MolMed 6, 430-439.
64. Terai K, Iwai A, Kawabata S, Sasamata M, Miyata K, Yamaguchi T (2001) Apolipoprotein E deposition and astroglio-sis are associated with maturation ofbeta-amyloid plaques in betaAftPPswe transgenic mouse: Implications for the patho-genesis of Alzheimer's disease. Brain Res 900, 48-56.
65. Schwab C, Hosokawa M, McGeer PL (2004) Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp Neurol 188, 52-64.
66. Burns MP, Noble WJ, Olm V, Gaynor K, Casey E, LaFran-cois J, Wang L, Duff K (2003) Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques. Brain Res Mol Brain Res 110, 119-125.
67. Kulnane LS, Lamb BT (2001) Neuropathological characterization of mutant amyloid precursor protein yeast artificial chromosome transgenic mice. Neurobiol Dis 8, 982-992.
68. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Sai-do TC, Selkoe DJ(1996) Sequence of deposition ofheteroge-neous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. NeurobiolDis 3, 16-32.
69. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM (1999) Apolipoprotein E is essential for amyloid deposition in the AftPP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U SA 96, 1523315238.
70. Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Ashe KH, Irizarry MC, Hyman BT (2000) Apolipoprotein E facilitates neuritic and cerebrovas-cular plaque formation in an Alzheimer's disease model. Ann Neurol 47, 739-747.
71. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schur-mann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J (2009) Genome-wide association study identifies variants at CLU and PI-CALM associated with Alzheimer's disease. Nat Genet 41, 1088-1093.
72. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De DP, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzou-rio C, Gut I, Van BC, Alperovitch A, Lathrop M, Amouyel P (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41, 1094-1099.
73. Choi-Miura NH, Ihara Y, Fukuchi K, Takeda M, Nakano Y, Tobe T, Tomita M (1992) SP-40,40 is a constituent of Alzheimer's amyloid. Acta Neuropathol 83, 260-264.
74. Matsubara E, Soto C, Governale S, Frangione B, Ghiso J (1996) Apolipoprotein J and Alzheimer's amyloid beta solubility. Biochem J 316 (Pt 2), 671-679.
75. DeMattos RB, O'dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR, Paul SM, Aronow BJ, Holtzman DM (2002) Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model ofAlzheimer's disease. Proc Natl Acad Sci USA 99, 10843-10848.
76. Morgan BP, Gasque P (1996) Expression of complement in the brain: role in health and disease. Immunol Today 17, 461-466.
77. Bradt BM, Kolb WP, Cooper NR (1998) Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med 188, 431-438.
78. Jiang H, Burdick D, Glabe CG, Cotman CW, Tenner AJ (1994) beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J Immunol 152, 5050-5059.
79. Yasojima K, Schwab C, McGeer EG, McGeer PL (1999) Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am J Pathol 154, 927936.
80. Eikelenboom P, Stam FC (1982) Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol 57, 239-242.
81. Loeffler DA (2004) Using animal models to determine the significance of complement activation in Alzheimer's disease. J Neuroinflammation 1, 18.
82. Webster S, O'Barr S, Rogers J (1994) Enhanced aggregation and beta structure of amyloid beta peptide after coincubation with C1q. J Neurosci Res 39, 448-456.
83. Shen Y, Halperin JA, Lee CM (1995) Complement-mediated neurotoxicity is regulated by homologous restriction. Brain Res 671, 282-292.
84. Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, Masliah E (2002) Prominent neurodegenera-tion and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci USA 99, 1083710842.
85. Fonseca MI, Zhou J, Botto M, Tenner AJ (2004) Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J Neurosci 24, 6457-6465.
86. Zhou J, Fonseca MI, Pisalyaput K, Tenner AJ (2008) Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease. J Neurochem 106, 2080-2092.
87. Matsuoka Y, Picciano M, Malester B, LaFrancois J, Zehr H, Daeschner JM, Olschowka JA, Fonseca MI, O'Banion MK, Tenner AJ, Lemere CA, Duff K (2001) Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am J Pathol 158, 1345-1354.
88. Fan R, DeFilippis K, Van Nostrand WE (2007) Induction of complement proteins in a mouse model for cerebral mi-crovascular A beta deposition. J Neuroinflammation 4, 22.
89. Reichwald J, Danner S, Wiederhold KH, Staufenbiel M (2009) Expression of complement system components during aging and amyloid deposition in AftPP transgenic mice. J Neuroinflammation 6, 35.
90. Webster SD, Tenner AJ, Poulos TL, Cribbs DH (1999) The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation. Neurobiol Aging 20, 297-304.
91. Ebanks RO, Isenman DE (1996) Mouse complement component C4 is devoid ofclassical pathway C5 convertase subunit activity. Mol Immunol 33, 297-309.
92. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute menin-goencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61, 46-54.
93. Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAftPP mouse. Nature 400, 173-177.
94. Abraham CR, Selkoe DJ, Potter H (1988) Immunochem-ical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52, 487-501.
95. Kalaria RN, Grahovac I (1990) Serum amyloid P immunore-activity in hippocampal tangles, plaques and vessels: implications for leakage across the blood-brain barrier in Alzheimer's disease. Brain Res 516, 349-353.
96. McGeer EG, Yasojima K, Schwab C, McGeer PL (2001) The pentraxins: possible role in Alzheimer's disease and other innate inflammatory diseases. Neurobiol Aging 22, 843-848.
97. Ying SC, Gewurz AT, Jiang H, Gewurz H (1993) Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of C1q. J Immunol 150, 169-176.
98. Shi J, Perry G, Aliev G, Smith MA, Ashe KH, Friedland RP (1999) Serum amyloid P is not present in amyloid beta deposits ofa transgenic animal model. Neuroreport 10, 32293232.
99. Shi J, Perry G, Berridge MS, Aliev G, Siedlak SL, Smith MA, LaManna JC, Friedland RP (2002) Labeling ofcerebralamyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. J Nucl Med 43, 1044-1051.
100. Winkler DT, Bondolfi L, Herzig MC, Jann L, Calhoun ME, Wiederhold KH, Tolnay M, Staufenbiel M, Jucker M (2001) Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci 21, 1619-1627.
101. Van Gool D., De Strooper B., Van Leuven F., Triau E, Dom R (1993) alpha 2-Macroglobulin expression in neuritic-type plaques in patients with Alzheimer's disease. Neurobiol Aging 14, 233-237.
102. Hughes SR, Khorkova O, Goyal S, Knaeblein J, Heroux J, Riedel NG, Sahasrabudhe S (1998) Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proc Natl Acad Sci USA 95, 3275-3280.
103. Kondo T, Tooyama I (2003) Deposition of Alpha2-Macroglobulin in Fibrillar Type of Senile Plaques in the Brain of PS/A(PP-Transgenic Mice. ActaHistochem Cytochem 36, 215-220.
104. Eriksson S, Janciauskiene S, Lannfelt L (1995) Alpha 1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation. Proc Natl Acad Sci USA 92, 2313-2317.
105. Janciauskiene S, Rubin H, Lukacs CM, Wright HT (1998) Alzheimer's peptide Abeta1-42 binds to two beta-sheets of alpha1-antichymotrypsin and transforms it from inhibitor to substrate. J Biol Chem 273, 28360-28364.
106. Nilsson LN, Bales KR, DiCarlo G, Gordon MN, Morgan D, Paul SM, Potter H (2001) Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. J Neurosci 21, 14441451.
107. Verbeek MM, Otte-Holler I, Westphal JR, Wesseling P, Ruiter DJ, de Waal RM (1994) Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease. Am J Pathol 144, 104-116.
108. Verbeek MM, Otte-Holler I, Wesseling P, Ruiter DJ, de Waal RM (1996) Differential expression of intercellular adhesion molecule-1 (ICAM-1) in the A beta-containing lesions in brains of patients with dementia of the Alzheimer type. Acta Neuropathol 91, 608-615.
109. Apelt J, Lessig J, Schliebs R (2002) Beta-amyloid-associated expression of intercellular adhesion molecule-1 in brain cortical tissue of transgenic Tg2576 mice. Neurosci Lett 329, 111-115.
110. Levy E, Sastre M, Kumar A, Gallo G, Piccardo P, Ghetti B, Tagliavini F (2001) Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients. J Neuropathol Exp Neurol 60, 94-104.
111. Olafsson I, Thorsteinsson L, Jensson O (1996) The molecular pathology of hereditary cystatin C amyloid angiopathy causing brain hemorrhage. Brain Pathol 6, 121-126.
112. Kaeser SA, HerzigMC, Coomaraswamy J, KilgerE, Selenica ML, Winkler DT, Staufenbiel M, Levy E, Grubb A, Jucker M (2007) Cystatin C modulates cerebral beta-amyloidosis. Nat Genet 39, 1437-1439.
113. Mi W, Pawlik M, Sastre M, Jung SS, Radvinsky DS, Klein AM, Sommer J, Schmidt SD, Nixon RA, Mathews PM, Levy E (2007) Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models. Nat Genet 39, 14401442.
114. Sun B, Zhou Y, Halabisky B, Lo I, Cho SH, Mueller-Steiner S, Devidze N, Wang X, Grubb A, Gan L (2008) Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron 60, 247-257.
115. Hashimoto T, Wakabayashi T, Watanabe A, Kowa H, Hosoda R, Nakamura A, Kanazawa I, Arai T, Takio K, Mann DM, Iwatsubo T (2002) CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV. EMBOJ 21, 1524-1534.
116. Kowa H, Sakakura T, Matsuura Y, Wakabayashi T, Mann DM, Duff K, Tsuji S, Hashimoto T, Iwatsubo T (2004) Mostly separate distributions of CLAC-versus A(40-or Thioflavin S-reactivities in senile plaques reveal two distinct subpopu-lations of (-amyloid deposits. Am J Pathol 165, 273-281.
117. Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X, Wang Y, Gonzales E, Holtzman DM, Lee JM (2009) Characterizing the appearance and growth of amyloid plaques in A(PP/PS1 mice. J Neurosci 29, 10706-10714
118. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de CA Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT, 2008 Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease, Nature, 451, 720-724